secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063953
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M
--------------------------------------------------------------------------

- Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.
- Non-GAAP pro forma adjusted EBITDA $11.4M (6.0% margin), up 49% vs $7.7M in Q1 2024; adjusted gross margin 70.3%.
- Lowered FY2025 net sales guidance to $808-816M (pro forma) from $818-826M; reaffirms adjusted EBITDA $82-86M and positive free cash flow.
- U.S. Spine Fixation +4%, BGT +5%, Global Orthopedics constant currency +11% YoY; TrueLok Elevate TBT System received FDA clearance.
- Management cites commercial channel optimization causing temporary softness; expects growth to normalize after distributor transitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000095017025063953/0000950170-25-063953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000095017025063953/ofix-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer